[Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide].
Odin. V I VI; Belikova. T V TV; Pushkova. E S ES; Barr. N A NA
Key Findings
- Significant improvements in mood, recent memory, anxiety and emotional stability after 60 days of DSIP treatment.
- Reduced post‑meal blood glucose levels (p = 0.033) and lower frequency of micro‑albuminuria (p = 0.011).
- Hormonal shifts: lower growth hormone, unchanged insulin and cortisol, and a non‑significant rise in DHEA‑S.
Practical Outcomes
- DSIP might offer modest benefits for mood, sleep and post‑meal glucose control in elderly diabetics, but the evidence comes from a very small, uncontrolled pilot. There’s no clear dosing guideline and safety data are limited, so it’s not ready for routine self‑experimentation. Anyone considering DSIP should proceed cautiously, track blood sugar and hormone levels, and view this as an experimental approach pending larger studies.
Summary
A tiny pilot study gave 11 older adults with diabetes a drug called Deltaran, which contains the peptide DS‑sleep‑induced peptide (DSIP), for two months. After treatment the participants reported better mood, memory, sleep and less anxiety, and their blood sugar after a meal dropped a bit. Some hormone levels also changed, but many results were small or not statistically clear.
Abstract
Delta-sleep induced peptide (DSIP) has a wide range of positive regulator properties. It is known as antioxidant, immunomodulator, antistressor and other, that important as for diabetes, and for aging mechanisms. Aim of the study was to investigate effects of treatment by DSIP-containing drug "Deltaran" in elderly diabetic patients. As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment. Blood samples took before and after 60 minutes after standard carbohydrates breakfast. After treatment were observed improvement of the parameters of quality of life on SCAG scale as the impairment of recent memory (p=0.003), mood depression (p=0.019), emotional lability (p=0.002) and anxiety (p=0.000). Also were observed improvement of quality of sleep and felling between meals in treating patients (p=0.010). Another positive tendencies consist of decrease of BP (ns), increase of ABI (ns), increase of pallestesia (p=0.017), decrease of MAU frequency (p=0.011) and decrease of glycaemia levels after load (p=0.033). And also after treatment were observed decrease of basal and reactive levels in blood of growth hormone (p=0.034 and p=0.005 accord.), insulin (ns), cortisol (ns) and on the contrary increase of dehydroepiandrosterone sulfate levels (ns). Main positive change observed in patients received only diabetic diet, where was a decrease of insulin resistance and in patients with latent autoimmune diabetes (type LADA), where was a increase insulin secretion and decrease of daily dose of insulin requiring. The pilot trial indicate beneficial antidiabetic and geroprotective effects of DSIP-contaning drug "Deltaran" in elderly diabetic patients.
Study Information
pubmed
2004